TNBC Treatment Resistance Research
Guide to the TNBC resistance section, including natural compounds, repurposed drugs, and emerging resistance-strategy pages
TNBC can become hard to treat when it adapts to chemotherapy.
Resistance often involves more than one shift at once.
EMT, cancer stem-cell behaviour, drug efflux, mitochondrial rewiring, and survival signalling can all move together.
This page is now the guide to the TNBC resistance section.
The detailed write-ups live on the child pages below.
In this section
This section mainly tracks preclinical research.
The Emerging Resistance Strategies page also includes a small number of early clinical combination signals because they show where resistance-directed treatment may be heading.
Do not add piperlongumine, pterostilbene, pitavastatin, or other agents on the basis of this section without oncology and pharmacy review.
Why chemo-resistance is such a big issue in TNBC
TNBC often behaves more aggressively than receptor-positive disease.
It also has fewer standard targeted options.
That makes treatment escape more consequential.
Common resistance themes include:
EMT and invasion
cancer stem-cell persistence
P-glycoprotein and other efflux pumps
AKT/STAT3 and related survival pathways
mitochondrial adaptation and apoptosis evasion
These themes help explain why natural compounds and repurposed drugs keep drawing attention.
Researchers are looking for agents that hit several of them at once.
Key pages in this section
The constantly updated treatment resistance research is divided into sub-sections.
Natural compounds
TNBC Natural Compounds in Treatment Resistance Research already covers pterostilbene, blueberry findings, piperlongumine, and the microRNA logic linking them to resistance research.
Off-label drugs
TNBC Off-Label Drugs in Treatment Resistance Research covers work on repurposed-drug leads such as pitavastatin, melatonin, and metformin.
Emerging strategies
Emerging Resistance Strategies covers RNA-level targeting and next-wave combination approaches.
How to use these pages
Start with the page that matches the type of idea you are checking.
Use the interaction and safety cautions to screen out weak self-directed add-ons.
Bring any shortlist to oncology and pharmacy review before acting on it.
What this does and does not mean in practice
Most of the strategies in this section are still not proven clinical ways to prevent or reverse TNBC resistance.
The most useful takeaways are:
natural compounds such as pterostilbene, blueberries, and piperlongumine are still preclinical leads
pitavastatin is an especially interesting repurposing lead, but not yet a validated TNBC treatment
some multi-target combinations are now generating real human efficacy data, but they are regimen-specific oncology treatments, not self-directed add-ons
resistance biology is becoming more targetable as researchers focus on EMT, stem-cell programs, efflux, apoptosis escape, and immune evasion together
Any addition during active treatment needs oncology and pharmacy review first.
That is especially true for concentrated supplements, off-label drugs, or multi-agent stacks.
Abraxane, Oxidative Stress, and Antioxidants: Useful guide to Abraxane’s taxane mechanism, oxidative-stress questions, and supplement considerations during treatment. If you are starting to see progression or just not getting the results you desire form Abraxane the guide may help you understand the drugs and how you might be able to support it's mechanisms of action.
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.